Loading…
Eledon Pharmaceuticals, Inc. is projected to rise to $6.38 by 2027, a +64% move from its current price of $3.90. ELDN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.79 | $3.90 | $4.03 | +0.13% |
| May 30 | $3.74 | $3.91 | $4.08 | +0.25% |
| May 31 | $3.71 | $3.91 | $4.13 | +0.38% |
| Jun 1 | $3.69 | $3.92 | $4.17 | +0.50% |
| Jun 2 | $3.66 | $3.92 | $4.20 | +0.63% |
| Jun 3 | $3.64 | $3.93 | $4.24 | +0.75% |
| Jun 4 | $3.63 | $3.93 | $4.27 | +0.88% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.63 | $3.93 | $4.27 | +0.88% |
| Week 2 | $3.54 | $3.97 | $4.45 | +1.76% |
| Week 3 | $3.48 | $4.00 | $4.61 | +2.66% |
| Week 4 | $3.43 | $4.04 | $4.75 | +3.56% |
| Week 5 | $3.39 | $4.07 | $4.89 | +4.47% |
| Week 6 | $3.37 | $4.11 | $5.02 | +5.39% |
| Week 7 | $3.34 | $4.15 | $5.15 | +6.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Its lead compound tegoprubart is an IgG1 anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation.
Eledon is headquartered in Irvine, California. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.
Eledon Pharmaceuticals, Inc. trades in the healthcare space under the symbol ELDN. The current price is $3.89 and the company has an approximate market capitalization of $300.26M. It ranks 3534 by market cap.
The near-term outlook blends a bullish technical backdrop with a multi-year forecast showing meaningful upside. The shares are positioned to move within a path that projects growth beyond the current level, with multi-year expectations highlighting a rising average price through 2030 and into the 2040s and 2050s.
A major floor 49.5% below — a decisive break under it would weaken the trend.
The nearest floor, 15.4% below — buyers have tended to step in here.
The nearest ceiling, 6.2% above — a clean break opens room to run.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key ELDN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELDN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.88 | Buy | $3.87 | Buy |
| MA 10 | $3.82 | Buy | $3.83 | Buy |
| MA 20 | $3.78 | Buy | $3.76 | Buy |
| MA 50 | $3.46 | Buy | $3.46 | Buy |
| MA 100 | $2.84 | Buy | $3.10 | Buy |
| MA 200 | $2.65 | Buy | $2.91 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.28 | Neutral |
| Stoch RSI (14) | 66.52 | Neutral |
| CCI (20) | 69.90 | Neutral |
| Williams %R (14) | -13.51 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 0.52 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 86.49 | Sell |
| TRIX (15) | 0.52 | Buy |
| Awesome (5,34) | 0.19 | Buy |
| Ultimate (7,14,28) | 57.16 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 3.94 | Sell |
| ADX (14) | 20.19 | Buy |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bullish. RSI(14) is 60, indicating positive momentum, with a simple moving average of $3.41 for the 50-day window and $2.63 for the 200-day window.
Support is reported at $3.20 and resistance at $4.14, framing a near-term range as the stock tests upside potential. The 30-day trading range spans from $3.13 to $4.83, suggesting room for near-term movement within that band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.62 | $3.90 | $6.29 | 0% | Neutral | |
| $5.00 | $6.38 | $8.67 | +64% | Bullish | |
| $5.89 | $7.76 | $10.96 | +99% | Bullish | |
| $6.37 | $8.61 | $12.56 | +121% | Bullish | |
| $6.61 | $9.15 | $13.70 | +135% | Bullish | |
| $8.28 | $11.71 | $17.94 | +200% | Bullish | |
| $10.04 | $14.48 | $22.65 | +271% | Bullish | |
| $11.71 | $17.20 | $27.41 | +341% | Bullish | |
| $13.90 | $20.80 | $33.72 | +433% | Bullish | |
| $14.03 | $21.36 | $35.18 | +448% | Bullish | |
| $25.18 | $41.47 | $73.01 | +963% | Bullish | |
| $41.30 | $78.09 | $151.47 | +19.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.62 | $3.90 | $4.60 | +0.00% |
| June 2026 | $3.47 | $4.09 | $4.94 | +4.88% |
| July 2026 | $3.68 | $4.37 | $5.36 | +6.86% |
| August 2026 | $3.70 | $4.43 | $5.50 | +1.41% |
| September 2026 | $3.68 | $4.44 | $5.55 | +0.07% |
| October 2026 | $3.85 | $4.67 | $5.89 | +5.19% |
| November 2026 | $4.01 | $4.88 | $6.21 | +4.60% |
| December 2026 | $4.01 | $4.91 | $6.29 | +0.58% |
Click any year to see its month-by-month ELDN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Eledon Pharmaceuticals, Inc.'s 2026 outlook centres on $3.90, within a $1.62 to $6.29 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ELDN could reach as high as $8.67, with a base case around $6.38 and support toward $5.00 — roughly +64% from $3.90. Buyers look set to stay in control over this stretch.
Expect ELDN to range from $5.89 to $10.96 through 2028. The $7.76 average target implies a +99% move from current prices. That is up +22% on the projected 2027 average. Momentum favours further upside here.
The ELDN price prediction for 2029 points to an average of $8.61 (low $6.37, high $12.56) — a potential gain of +121% on today's $3.90. Buyers look set to stay in control over this stretch.
In 2030, ELDN is projected to trade between $6.61 and $13.70, averaging $9.15 — a potential gain of +135% from today's $3.90. That is up +6% on the projected 2029 average. Momentum favours further upside here.
Eledon Pharmaceuticals, Inc.'s 2031 outlook centres on $11.71, within a $8.28 to $17.94 range. That is up +28% on the projected 2030 average. That marks a +200% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ELDN could reach as high as $22.65, with a base case around $14.48 and support toward $10.04 — roughly +271% from $3.90. Momentum favours further upside here.
Expect ELDN to range from $11.71 to $27.41 through 2033. The $17.20 average target implies a +341% move from current prices. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ELDN price prediction for 2034 points to an average of $20.80 (low $13.90, high $33.72) — a potential gain of +433% on today's $3.90. Momentum favours further upside here.
In 2035, ELDN is projected to trade between $14.03 and $35.18, averaging $21.36 — a potential gain of +448% from today's $3.90. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Eledon Pharmaceuticals, Inc.'s 2040 outlook centres on $41.47, within a $25.18 to $73.01 range. That is up +94% on the projected 2035 average. That marks a +963% change versus current levels. Momentum favours further upside here.
By 2050, ELDN could reach as high as $151.47, with a base case around $78.09 and support toward $41.30 — roughly +19.0x from $3.90. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELDN today (≈ 256.410256 ELDN) could be worth
$20,023.74
+$19,023.74 (+1902%) by 2050 · US Dollar
Based on the average projected ELDN price of $78.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELDNwould be worth at today's price.
$1,000 invested in ELDN on May 27, 2025 (≈ 317.460308 ELDN) would be worth
$1,238.1
+$238.1 (+23.8%) today · 1.24× · US Dollar
Based on a ELDN entry price of $3.15 vs. today's $3.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.84 | $1,015.63 | +1.6% |
| 1 month ago | $3.46 | $1,127.17 | +12.7% |
| 3 months ago | $2.42 | $1,611.57 | +61.2% |
| 6 months ago | $1.63 | $2,392.64 | +139.3% |
| 1 year ago | $3.15 | $1,238.1 | +23.8% |
| All time (5.0y) ago | $9.28 | $420.26 | -58.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELDN forecast.
Our base-case forecast reaches $7.80 around 2029.
Implied market cap at $7.80: $602.07M
The year-by-year forecast shows a clear long-term upside trajectory. In 2026 the min is $1.62, the avg is $3.89 and the max is $6.36, with ROI of 0 and a Neutral sentiment.
From 2027 to 2030 the Avg prices rise to $6.46 (2027), $9.14 (2030) and beyond, with ROIs of 66.2%, 134.9% respectively as sentiment shifts to Bullish. The 2031–2035 period continues the uptrend with Avg prices of $11.67 (2031), $14.49 (2032), $17.31 (2033), $20.85 (2034), and $21.23 (2035), and progressively higher ROIs up to 445.8% by 2035.
The forecast accelerates into the 2040s with an Avg of $41.50 and a max of $74.68 in 2040 (ROI 966.9%), and then to an Avg of $77.61 with a max of $154.42 in 2050 (ROI 1895%). These figures reflect bullish sentiment on a multi-year horizon, but they are estimates, not guarantees, and depend on clinical results, regulatory outcomes, and eventual commercialization.
Tap a question to reveal the answer.
In 2030 the forecast shows an Avg price of $9.14, a min of $6.51 and a max of $13.88, with an estimated ROI of 134.9% and bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with Avg prices rising to $6.46 (2027), $9.14 (2030), $41.50 (2040) and $77.61 (2050). ROIs reach 66.2% by 2027, 134.9% by 2030, and 1895% by 2050, though these are estimates and not guarantees.
The 2040 forecast shows an Avg of $41.50 with a max of $74.68, and the 2050 forecast shows an Avg of $77.61 with a max of $154.42. This suggests that surpassing $50 could occur within the forecast horizon, particularly by 2040 in the max scenario.
Current price is $3.89 and market capitalization is $300.26M.
The 30-day range is $3.13 to $4.83, with support at $3.20 and resistance at $4.14.
Eledon Pharmaceuticals, Inc. Community Discussion
0Share your Eledon Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.